Citi Keeps Hold on Bristol-Myers Squibb Despite Soaring Earnings

Citi analyst Geoff Meacham maintained his Hold rating on Bristol-Myers Squibb (BMY) and set a price target of $70.00.

The decision comes after the company's latest earnings release for the quarter ending June 30, which reported a quarterly revenue of $12.97 billion and a net profit of $3.32 billion.

This is in contrast to last year's figures, where the company earned a revenue of $12.27 billion and had a net profit of $1.31 billion.

Meacham, who has a 5-star analyst rating with an average return of 15.4% and a 59.62% success rate, focuses on stocks in the Healthcare sector, including Merck & Company, Pfizer, and Eli Lilly & Co.